Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy

Area of Science:

• Immunology
• Oncology
• Vaccinology

Background:

• Cancer immunotherapy failure is linked to immunological tolerance to tumor-associated antigens (TAAs).
• TAAs are also present in healthy tissues, complicating targeted immune responses.
• Overcoming this tolerance is crucial for developing effective cancer treatments.

Purpose of the Study:

• To investigate the effects of prostate cancer development on oncogene TAA-specific tolerance.
• To test if tolerance can be broken using a modified vaccinia virus vaccine.
• To evaluate the anti-tumor efficacy of breaking tolerance.

Main Methods:

• Utilized transgenic adenocarcinoma of mouse prostate (TRAMP) mice with prostate-specific SV40 T antigen (Tag) expression.
• Immunized young, tumor-free TRAMP mice with a vaccinia construct encoding Tag epitopes.
• Assessed the generation of Tag-specific cytotoxic T cells (CTLs) and their anti-tumor activity in vivo.

Main Results:

• Tag expression correlated with prostate malignancy but induced peripheral tolerance in young TRAMP mice.
• Vaccination successfully broke tolerance, priming Tag-specific CTLs in young mice.
• These CTLs demonstrated significant anti-tumor efficacy against established prostate tumors.
• Older TRAMP mice with tumors failed to generate CTLs upon immunization, indicating tolerance persistence.

Conclusions:

• Peripheral tolerance to oncogenes can be overcome by specific immunization for anti-tumor therapy.
• The ability to generate oncogene-specific CTLs is impaired in tumor-bearing hosts.
• Tumor progression and increased oncogene expression exacerbate tolerance, hindering therapeutic efficacy.